← Back to Search

Competitive Inhibitor

Phosphatidylserine for Type 2 Diabetes (ADAM17 Trial)

N/A

Recruiting

Research Sponsored by University of Missouri-Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Men and women with a BMI of 25-39 kg/m2, who are 45-64 years of age at randomization

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 4 weeks

Awards & highlights

ADAM17 Trial Summary

This trial will test whether the dietary supplement phosphatidylserine can improve vascular function and insulin-stimulated blood flow in people with type 2 diabetes.

Who is the study for?

This trial is for men and women aged 45-64 with Type 2 Diabetes, a BMI of 25-39 kg/m2, and no recent significant weight change. It excludes those with active cancer, autoimmune diseases, heavy alcohol use, chronic kidney or liver disease, current smokers, cardiovascular conditions, on immunosuppressants or hormone therapy.Check my eligibility

What is being tested?

The study tests if phosphatidylserine (PS), a dietary supplement that inhibits ADAM17 enzyme activity can improve blood flow and vascular function in people with Type 2 Diabetes. Participants will either receive PS or a placebo to compare effects.See study design

What are the potential side effects?

While the side effects of phosphatidylserine are not detailed here, common ones may include stomach upset and insomnia. Placebos typically have no active ingredients but can cause perceived side effects due to expectations.

ADAM17 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 45-64 years old with a BMI of 25-39.

ADAM17 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 4 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 4 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 4 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Insulin-stimulated blood flow

Secondary outcome measures

Change in Vascular function

ADAM17 Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Phosphatidylserine SupplementationExperimental Treatment1 Intervention

Study participants will receive 4 weeks of supplementation with 900mg phosphatidylserine supplements.

Group II: PlaceboPlacebo Group1 Intervention

Study participants will receive 4 weeks of supplementation with 900mg placebo supplements

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Phosphatidylserine

2020

Completed Phase 2

~240

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Missouri-ColumbiaLead Sponsor

362 Previous Clinical Trials

628,080 Total Patients Enrolled

Media Library

Phosphatidylserine (Competitive Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04557228 — N/A

Type 2 Diabetes Research Study Groups: Placebo, Phosphatidylserine Supplementation

Type 2 Diabetes Clinical Trial 2023: Phosphatidylserine Highlights & Side Effects. Trial Name: NCT04557228 — N/A

Phosphatidylserine (Competitive Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04557228 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially join this research endeavor?

"To partake in this diabetes mellitus type 2 study, a candidate must be between 45 and 64 years of age. 34 participants are sought for the trial."

Answered by AI

Does this research project still have any openings for participants?

"According to clinicaltrials.gov, this trial has concluded its recruitment process as of April 20th 2022. Although the study is no longer searching for candidates, there are 1,400 other medical trials still actively seeking patients at present."

Answered by AI